MarginsXMarginsX
Home › Markets › Health Care › DRMA

Dermata Therapeutics Inc. (DRMA)

DRMA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5985
-3.65% on the day
Market cap
$3.0M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerDRMA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001853816

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
6.5 months
$4.8M cash at September 30, 2026
Share count, 1 year
+380.3%
2025-11-12 to 2026-11-09 · +23089.8% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$1K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern for the one-year period following the date that these financial statements were issued."
10-Q 2026-11-10
Cash and burn$4.8M cash; operating cash flow -$2.2M a quarter.Report 2026-09-30
Shares outstanding4,930,207 (2026-11-09); 1,026,457 a year earlier; 3,189,034 three years earlier. 3y figure adjusted for splits (1-for-150 overall).Cover page 2026-11-09
Reverse splits, 3 years2; latest 1-for-10 on 2025-08-01Source 2025-08-01
Shelf and offerings, 12 months3 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-01-27
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-08-17
AuditorCBIZ CPAs P.C., San Diego, California, United States; changed auditors 2 times in 24 months8-K 4.01 2026-02-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1K, sold $13 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$74K-$2.8M-$2.6M$4.8MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$3.0M-$2.4M$4.4MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$1.8M-$2.5M$6.9MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$1.9M-$1.4M$7.5MNo debt tagsNeeds four quarters10-K 2026-03-26
Q3 2025
2025-09-30
Not filed-$1.7M-$1.8M$4.7MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$1.7M-$2.7M$6.5MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$2.3M-$1.9M$9.7MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$3.2M-$2.9M$3.2MNo debt tagsNeeds four quarters10-K 2026-03-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-18.7%
1 month-27.8%
3 months-60.4%
Year to date-73.2%
1 year-80.2%
From 52-week high-80.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NRSNNeuroSense Therapeutics Ltd.$1.56-7.40%$3.0M
MBIOMustang Bio Inc.$0.3947-6.34%$3.0M
ERNAErnexa Therapeutics Inc.$1.69+0.60%$2.9M
GRIGRI Bio Inc.$1.40-18.60%$3.1M
APUSApimeds Pharmaceuticals US Inc.$2.04-8.52%$3.1M
PPBTPurple Biotech Ltd.$1.68+3.70%$2.7M
RDHLRedhill Biopharma Ltd.$0.3605-3.87%$3.2M
MDCXMedicus Pharma Ltd. Common Stock$1.69-13.33%$3.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier